<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03640871</url>
  </required_header>
  <id_info>
    <org_study_id>F-18-06-AWC019</org_study_id>
    <nct_id>NCT03640871</nct_id>
  </id_info>
  <brief_title>HEAL Study: Healing Results, Efficacy and Acceptability of a New Contact Layer</brief_title>
  <acronym>HEAL</acronym>
  <official_title>Assessment of Efficacy, Tolerance and Acceptability for the Wound Dressing URGO AWC_019 in the Local Treatment of Acute Wounds, Chronic Wounds and Epidermolysis Bullosa Skin Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires URGO</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires URGO</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of efficacy, tolerance and acceptability for the wound dressing URGO AWC_019 in
      the treatment of acute wounds, chronic wounds and epidermolysis bullosa skin lesions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-comparative clinical study, conducted in France, to evaluate efficacy, tolerance and
      acceptability for the wound dressing URGO AWC_019 in the treatment of acute wounds, chronic
      wounds and epidermolysis bullosa skin lesions
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative evolution of the wound surface (in %) at week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Relative evolution of the wound surface (in %) at week 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Pain on wound URGO AWC_019 dressing removal (measured thanks to Analogical Visual Scale: no pain = 0 mm and unbearable pain = 100 mm)</measure>
    <time_frame>4 weeks</time_frame>
    <description>- Pain on wound URGO AWC_019 dressing removal (measured thanks to Analogical Visual Scale: no pain = 0 mm and unbearable pain = 100 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Wound dressing safety (occurrence of adverse events)</measure>
    <time_frame>4 weeks</time_frame>
    <description>- Wound dressing safety (occurrence of adverse events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Percentage of healed wounds (healing rate) after 4 weeks of treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>- Percentage of healed wounds (healing rate) after 4 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Wound healing time (in days)</measure>
    <time_frame>4 weeks</time_frame>
    <description>- Wound healing time (in days)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Wound</condition>
  <arm_group>
    <arm_group_label>URGO AWC_019 dressing (AWC=Advanced Wound Care)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>URGO AWC_019 dressing (AWC=Advanced Wound Care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>URGO AWC_019 dressing (AWC=Advanced Wound Care)</intervention_name>
    <description>URGO AWC_019 dressing 10x10 cm (AWC=Advanced Wound Care)</description>
    <arm_group_label>URGO AWC_019 dressing (AWC=Advanced Wound Care)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A. Related to every wounds types:

          -  Patient over 18 years old who has provided his/her written informed consent

          -  Patient affiliated to the French Social insurance

          -  Patient who can be monitored by the same investigation team throughout the whole
             duration of the study,

          -  Acute wound (postoperative non-cavitary and non-sutured wound, superficial, middle or
             deep second degree burn, dermabrasion) or chronic wound (venous or mixed leg ulcer,
             pressure ulcer) or epidermolysis bullosa skin lesion

          -  Use of a contact layer as a primary dressing justified by the wound

        B. Related to leg ulcer:

          -  Venous leg ulcer or mixed leg ulcer, i.e. with an Ankle Brachial Pressure Index (ABPI)
             not less than 0.7 and not more than 1.3, (0.7≤ABPI≤ 1.3)

          -  Patient who agrees to wear an effective venous compression system every day,
             associated with the trial dressing

        C. Related to pressure ulcer:

          -  Stage 2, 3 according to the EPUAP (European Pressure Ulcer Advisory Panel)
             classification system

          -  Wound on the pelvis (trochanter, ischio or sacrum) or on the heel

        Exclusion Criteria:

          -  Patient under authorship or guardianship

          -  Woman of child-bearing potential who has no effective contraception method

          -  Pregnant or breastfeeding woman

          -  Patient taking part in another clinical trial

          -  Patient with a known allergy to carboxymethylcellulose (hydrocolloid),

          -  Patient with a severe illness that might lead to the premature discontinuation of the
             trial before the 4 weeks of treatment

          -  Wound requiring surgical treatment or for which surgery is scheduled during the 4
             weeks after inclusion

          -  Patient with an evolving neoplasia condition, treated by radiotherapy, chemotherapy or
             hormone therapy

          -  Malignant wound

          -  Patient with a systemic infection not controlled by suitable antibiotic treatment,

          -  Wound which is clinically infected
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clémence Ms Tumba, PharmD</last_name>
    <phone>++33380447409</phone>
    <email>c.tumba@fr.urgo.com</email>
  </overall_contact>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

